Aquestive Therapeutics (AQST) EBITDA (2017 - 2026)

Aquestive Therapeutics' EBITDA history runs 10 years deep, the most recent figure standing at -$8.1 million for Q1 2026.

• In Q1 2026, EBITDA rose 64.86% year-over-year to -$8.1 million; the TTM figure through Mar 2026 stood at -$68.9 million (down 27.05% YoY), while the FY2025 annual figure was -$83.8 million, down 89.83% from the prior year.
• EBITDA was -$8.1 million for Q1 2026 at Aquestive Therapeutics, up from -$31.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $8.1 million in Q1 2023 to a low of -$31.9 million in Q4 2025.
• Historically, EBITDA has averaged -$11.7 million across 5 years, with a median of -$12.5 million in 2022.
• The sharpest annual moves came in 2023 and 2024: EBITDA surged 161.03% in 2023, then plunged 465.55% in 2024.
• A 5-year view of EBITDA shows it stood at -$12.4 million in 2022, then jumped by 34.33% to -$8.1 million in 2023, then plunged by 110.27% to -$17.1 million in 2024, then tumbled by 86.81% to -$31.9 million in 2025, then surged by 74.71% to -$8.1 million in 2026.
• The last three EBITDA figures came in at -$8.1 million (Q1 2026), -$31.9 million (Q4 2025), and -$15.4 million (Q3 2025), per Business Quant data.